Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis
Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis
The purpose of this research study is to evaluate the safety and effectiveness of Interferon
 gamma-1b (IFN-g 1b) on lung function when given to patients with cystic fibrosis by
 inhalation (breathed into the lungs) three times a week for 12 weeks.

 The FDA has not approved Interferon gamma-1b for use with cystic fibrosis patients, which is
 the condition being examined in this study.
Key inclusion criteria:

 -  At least 12 years of age

 -  Diagnosis of cystic fibrosis with mild to moderate pulmonary impairment

 -  Must be receiving ongoing chronic treatment with TOBI (inhaled tobramycin) OR not
 receiving ongoing chronic treatment with TOBI and no use of TOBI or other inhaled
 antibiotic within 4 weeks prior to study drug administration·

 -  Other specific diagnostic indicators of CF and other factors must meet minimum
 requirements.